Welcome to Module 4

 

This module is introduced by Alastair O’Brien, Professor of Hepatology at the Royal Free Hospital and University College London, UK, together with Gemma Wells, Clinical Researcher at the Royal Free Hospital.

 

They will guide you through one of the most critical aspects of clinical trial design: the selection, definition, and evaluation of study endpoints. The choice of endpoints is fundamental to the success of any clinical study, as it determines how treatment effects are measured, how results are interpreted, and ultimately how evidence influences clinical practice.

 

Selecting appropriate primary and secondary endpoints requires balancing scientific rigor, clinical relevance, feasibility, and regulatory expectations. A well-chosen primary endpoint should directly address the main study objective and provide a robust measure of treatment efficacy or effectiveness. Secondary endpoints, in turn, can provide important complementary information on safety, disease progression, patient experience, and other clinically meaningful outcomes.

 

In this module, you will explore the different types of endpoints used in prospective clinical research, including clinical outcomes, surrogate markers, patient-reported outcomes, and exploratory measures. Particular attention is given to the strengths and limitations of each approach and to the importance of selecting endpoints that are relevant to patients, clinicians, researchers, and regulatory authorities.

 

The module also addresses the importance of predefined study protocols and statistical analysis plans. You will examine why endpoints, milestones, and subgroup analyses should be specified in advance, how protocol amendments should be approached, and the potential risks of introducing changes once a study is underway. Understanding these principles is essential for maintaining scientific validity, minimizing bias, and ensuring transparency in clinical research.

 

In addition, you will learn how endpoints are translated into practical data collection through the design of case report forms (CRFs). Effective CRFs are critical for ensuring that study data are complete, accurate, and capable of supporting reliable endpoint assessment.

 

Finally, the module explores the role of post-hoc analyses in clinical trials. While such analyses can generate valuable hypotheses and uncover clinically relevant insights, they must be interpreted cautiously due to the increased risk of bias and false-positive findings. Understanding both the opportunities and limitations of post-hoc analyses is essential for the critical appraisal of clinical research.

 

Through a series of focused lectures, this module will provide a practical framework for selecting meaningful endpoints, designing robust data collection strategies, and interpreting clinical trial results with methodological rigor.

 

 

Upon completing module 4, students will be able to:

 

• Understand and discuss the rationale for choosing specific primary and secondary endpoints, the role and limitations of surrogate, patient-reported, and exploratory outcomes.
• Understand the importance of predefined (and ideally published) study protocols, milestones, and subgroup analyses.
• Discuss when amendments to endpoints are appropriate.
• Design a case report form (CRF) designed to capture relevant information to record endpoints.
• Understand the value of post hoc analysis in clinical trials.